Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919132 | PMC |
http://dx.doi.org/10.1002/ctm2.283 | DOI Listing |
J Neurosurg
January 2025
Departments of2Neurological Surgery and.
Objective: Skull base chordomas (SBCs) often present with cranial nerve (CN) VI deficits. Studies have not assessed the prognosis and predictive factors for CN VI recovery among patients presenting with CN VI deficits.
Methods: The medical records of patients who underwent resection for primary chordoma from 2001 to 2020 were reviewed.
JSES Int
November 2024
Queensland Unit for Advanced Shoulder Research (QUASR), Queensland University of Technology, Brisbane, Australia.
Background: Frozen shoulder (FS) is a debilitating inflammatory condition affecting the shoulder capsule that causes significant pain and stiffness. Its etiology, pathophysiology, and treatment remain poorly understood. Although regarded as self-limiting, FS can have profound implications on the activities of daily living and usually takes 1-4 years to resolve on its own accord.
View Article and Find Full Text PDFCureus
December 2024
Medical Education, ABWA Medical College, Faisalabad, PAK.
Background: The inclusion of artificial intelligence in medical education, specifically through the use of ChatGPT (OpenAI, San Francisco, CA), has transformed learning and generated many ethical questions. This study aims to analyze the medical students' ethical concerns about using ChatGPT in medical education, focusing on privacy, accuracy, and professional integrity.
Methods: The study format was a cross-sectional survey distributed to 219 medical students at ABWA Medical College, Pakistan.
Arch Rehabil Res Clin Transl
December 2024
Northwestern University Feinberg School of Medicine, Department of Physical Therapy and Human Movement Sciences, Chicago, IL.
Objective: To analyze changes in balance and gait in patients undergoing rehabilitation postcraniectomy and postcranioplasty, including comparison of outcomes across time periods, rate of change, and among diagnoses.
Design: Retrospective cohort study.
Setting: Inpatient rehabilitation.
Cancer Chemother Pharmacol
January 2025
Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
Purpose: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of durvalumab, and exposure-response for efficacy and safety (ERES) of TOPAZ-1.
Methods: The PopPK model for durvalumab was updated using data from 5 previously analysed studies and TOPAZ-1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!